Biological
IMC-1121B (ramucirumab)
IMC-1121B (ramucirumab) is a biological therapy with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
100%(4 trials)
Phase Distribution
Ph phase_2
4
100%
Phase Distribution
0
Early Stage
4
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
4(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(4)
Detailed Status
Completed4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 24 (100.0%)
Trials by Status
completed4100%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_2
A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT01160744
completedphase_2
A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer
NCT00683475
completedphase_2
A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma
NCT00533702
completedphase_2
A Study of IMC-1121B (Ramucirumab) in Colorectal Cancer
NCT00862784
Clinical Trials (4)
Showing 4 of 4 trials
NCT01160744Phase 2
A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT00683475Phase 2
A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer
NCT00533702Phase 2
A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma
NCT00862784Phase 2
A Study of IMC-1121B (Ramucirumab) in Colorectal Cancer
All 4 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 4